Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer-Reference-Cited by-同舟云学术

Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer

Published:2017-11-30 Issue:2 Volume:168 Page:457-465
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Reinert T.^ORCID,Debiasi M.,Bines J.,Barrios C. H.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4593-x/fulltext.html

Reference36 articles.

1. Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO–ESMO International consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. https://doi.org/10.1093/annonc/mdx036

2. Rugo HS, Rumble RB, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34(25):3069–3103

3. Saad ED (2011) Endpoints in advanced breast cancer: methodological aspects & clinical implications. Indian J Med Res 134:413–418

4. Bergh J, Jonsson PE, Lidbrink EK et al (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919–1925

5. Bonneterre J, Thurlimann B, Robertson J et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Eficacy and Tolerability study. J Clin Oncol 18:3748–3757

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the study of RNA-binding proteins in diabetic complications;Molecular Metabolism;2022-08

2. Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?;Clinical Breast Cancer;2021-08

3. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China;Frontiers in Oncology;2021-02-11

4. Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer;Cancer Management and Research;2019-01

5. Biomarkers in Breast Cancer;Biomarker - Indicator of Abnormal Physiological Process;2018-09-05